Dr. Reddy’s Laboratories has launched Nivorz (Nivolumab Biosimilar) in India. Nivroz is a biosimilar to Opdivo (nivolumab). The launch represents a significant milestone for Dr. Reddy’s, with Nivorz marking its entry into biosimilar immuno-oncology in India.
Developed and manufactured entirely in-house at Dr. Reddy’s biologics facility in Bachupally, Hyderabad, it reflects the company’s end-to-end capabilities across the biosimilar value chain, from development through commercialisation.
Sridevi Khambhampaty, Global Head of Biologics, Dr. Reddy’s Laboratories, said: The launch of Nivorz marks an important milestone for our biologics business. It reinforces our commitment to expanding patient access to high-quality biologic therapies, strengthens our oncology portfolio and reflects our continued focus on developing complex biosimilars.”
“As access to immunotherapy continues to be a challenge for many patients, we remain committed to improving access to high-quality treatment options through affordable biosimilars such as Nivroz,” MV Ramana, CEO – Global Generics, Dr. Reddy’s Laboratories, said in a release on Tuesday.
The immuno-oncology market in India, estimated at about ₹3,900 crore in 2025, is predominantly driven by checkpoint inhibitors such as nivolumab, pembrolizumab and toripalimab.
Published on September 15, 2026
